POTOMAC, MARYLAND — February 2, 2026 — Leads & Copy — IGC Pharma, Inc. (NYSE American:IGC) has reached approximately 70% of planned patient enrollment in its Phase 2 CALMA clinical trial, which is evaluating IGC-AD1 for the treatment of agitation associated with Alzheimer’s disease.
The company reports it has approximately 23 active sites across 26 locations, and enrollment is progressing across this clinical network. IGC anticipates completing enrollment by mid-2026. The company believes this milestone meaningfully reduces the primary operational risk for the trial and positions CALMA to progress toward database lock and topline results.
According to Ram Mukunda, CEO of IGC Pharma, reaching ~70% enrollment reflects improving execution and site productivity across their network. Mukunda said that enrollment is the final operational gate, and their focus is to complete enrollment efficiently while maintaining data quality and rigorous trial conduct.
IGC has continued to activate experienced sites and expand patient access through a hybrid, decentralized model in select geographies. The company expects enrollment progress to continue as additional site capacity comes online and newly activated sites ramp to steady-state contribution. In a randomized, double-blind, placebo-controlled study, efficacy outcomes are not analyzed on an ongoing interim basis to preserve blinding and trial integrity.
IGC-AD1 is an investigational, cannabinoid-based therapy being evaluated in a randomized, double-blind, placebo-controlled clinical trial designed to assess safety and efficacy in agitation associated with Alzheimer’s disease.
IGC Pharma (NYSE American: IGC) is a clinical-stage biotechnology company leveraging AI to develop treatments for Alzheimer’s and metabolic disorders. The company’s lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer’s dementia. Its pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. The company integrates AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With a complete patent portfolio, IGC Pharma aims to advance breakthrough therapies.
Source: IGC Pharma
